MEASLES VIRUS ANTIBODY RESPONSES IN CHILDREN RANDOMLY ASSIGNED TO RECEIVE STANDARD-TITER EDMONSTON-ZAGREB MEASLES VACCINE AT 4.5 AND 9 MONTHS OF AGE, 9 MONTHS OF AGE, OR 9 AND 18 MONTHS OF AGE

Sunday, 25th of January 2015

MEASLES VIRUS ANTIBODY RESPONSES IN CHILDREN RANDOMLY ASSIGNED TO RECEIVE STANDARD-TITER EDMONSTON-ZAGREB MEASLES VACCINE AT 4.5 AND 9 MONTHS OF AGE, 9 MONTHS OF AGE, OR 9 AND 18 MONTHS OF AGE

Martins C¹, Garly ML¹, Bale C¹, Rodrigues A¹, Njie-Jobe J², Benn CS³, Whittle H², Aaby P³.

Author information

• ¹Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
• ²MRC Laboratories, Fajara, Gambia.
• ³Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Denmark.

 

J Infect Dis. 2014 Sep 1;210(5):693-700. doi: 10.1093/infdis/jiu117. Epub 2014 Mar 31.

 

Abstract below; full text is available to journal subscribers.

The World Health Organization recommends administration of measles vaccine (MV) at age 9 months in low-income countries. We tested the measles virus antibody response at 4.5, 9, 18, and 24 months of age for children randomly assigned to receive standard-titer Edmonston-Zagreb MV at 4.5 and 9 months, at 9 months, or at 9 and 18 months of age. At 4.5 months of age, 75% had nonprotective measles virus antibody levels. Following receipt of MV at 4.5 months of age, 77% (316/408) had protective antibody levels at 9 months of age; after a second dose at 9 months of age, 97% (326/337) had protective levels at 24 months of age. In addition, the response at both 9 and 24 months of age was inversely correlated with the antibody level at receipt of the first dose of MV, and the second dose of MV, received at 9 months of age, provided a significant boost in antibody level to children who had low antibody levels. In the group of 318 children who received MV at 9 months of age, with or without a second dose at 18 months of age, 99% (314) had protective levels at 24 months of age. The geometric mean titer at 24 months of age was significantly lower in the group that received MV at 4.5 and 9 months of age than in the group that received MV at 9 months of age (P = .0001). In conclusion, an early 2-dose MV schedule was associated with protective measles virus antibody levels at 24 months of age in nearly all children. Clinical Trials Registration. NCT00168558.

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.